The NOBLE study demonstrated mechanistic and clinical efficacy, safety, and tolerability of pegcetacoplan, a targeted C3 and C3b inhibitor, in patients with posttransplant recurrent C3G and primary IC-MPGN. The gene discussed is C3; the disease is complement 3 glomerulopathy.